In late 2016, shareholders were advised that 5 NDAs had been signed with international pharma, which was said to signal a growing level of interest in Phylogica’s progress. Subsequently, there have been no deals announced.
Meanwhile, since early 2016, peptide library and discovery company Peptidream has announced substantial deals with Genentech, Janssen, Asahi Kasei, Shionogi and Bayer.
Do those pharma which signed NDAs in 2016 still hold active interest in Phylogica’s technology or have they all now terminated discussions? Has there been any new interest from pharma since early 2017?
Why do you think Phylogica has lately failed to attract any committed interest from pharma while Peptidream has continued to sign new deals?
PYC Price at posting:
2.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)